The UK and US have agreed to a important commercial pact that will maintain zero levies on British drug shipments being sold in the American market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has pledged to increase spending on medicines through the National Health Service (NHS). This pledge secures that tariffs on these key products will stay at zero for a duration of 36 months.
This development follows recent warnings to dramatically increase duties on patented drug imports, with increases discussed reaching one hundred percent.
"This arrangement with the Britain strengthens the international landscape for innovative medicines and introduces long-overdue fairness to U.S.–U.K. drug exports," a release noted.
Commercial Impact
Pharmaceuticals are one of the the United Kingdom's biggest exports to the America, which is clearly the primary buyer for leading companies like GSK and AstraZeneca.
Export figures indicate that in the one-year period to the end of September, the UK sold pharmaceutical products worth £11.1bn to the US. This amount accounted for 17.4% of British export trade in that period.
"This guarantee safeguards jobs, increases funding and sets the stage for the UK to emerge as a international leader for life sciences," a minister remarked.
Detailed UK Commitments
The deal involves several key pledges from the British government:
- Higher Cost Ceiling: The UK will increase the cost ceiling at which it deems new treatments to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a target to double overall health service expenditure on drugs from 0.3% of Gross Domestic Product to 0.6% over the following ten-year period.
- Rebate Cap: The amount drug companies must pay back to the NHS to control costs will be capped at fifteen percent. Previously, refunds were more than twenty percent.
Broader Context
The pact comes amid a long-running tension between the sector and the UK government over drug pricing and NHS adoption.
The disagreement were intensified by arguments that American consumers were paying several times more for the same drugs than consumers in the UK and Europe.
Recently, several large manufacturing plans in the UK have been halted or scrapped, while multi-billion-dollar funding commitments have been pledged toward projects in the United States.
A senior figure publicly accepted that the NHS had to spend more on drugs, noting that its expenditure on drugs had shrunk as a percentage of its overall budget over the past decade.
